E-Prescribing and EPCS: Safer Workflows for Dermatology Teams

A prescription is not finished when someone clicks “send.” The medication must be appropriate, the instructions must be clear, the correct pharmacy must receive it, and the practice must know what to do when something goes wrong. Dermatology teams encounter these issues with topical treatments, systemic therapies, and occasional controlled medications. Electronic prescribing helps organize the process, but electronic prescribing of controlled substances—EPCS—adds specific identity, access, and signing requirements. The goal is not simply to replace paper. It is to build a prescribing workflow that is safe, traceable, and manageable on a busy clinic day. ## Understand Where Ordinary E-Prescribing Ends and EPCS Begins E-prescribing electronically transmits prescriptions to pharmacies. EPCS applies additional safeguards when the prescription is for a controlled substance under federal law. Most routine dermatology prescriptions, including many topical corticosteroids and antibiotics, are not controlled substances. An opioid prescribed after a procedure or a benzodiazepine prescribed for procedural anxiety would follow a controlled-substance workflow when clinically appropriate. Importantly, a medication can have strict dispensing requirements without being controlled. Isotretinoin, for example, has iPLEDGE REMS requirements but is not a federally controlled substance. EPCS does not replace REMS requirements, prior authorization, or clinical monitoring. ### Keep Three Rule Sets Separate Before implementing a workflow, distinguish: - **Federal EPCS requirements:** DEA rules governing compliant applications, identity proofing, access controls, authentication, and records. - **State requirements:** Prescribing authority, electronic-prescribing mandates, prescription drug monitoring program requirements, and medication-specific restrictions. - **Payer or program requirements:** Applicable Medicare Part D EPCS requirements and other contractual obligations. Federal rules permit EPCS when requirements are met; that does not mean every prescription is federally required to be electronic. Applicable mandates and exceptions must be checked separately. ## Set Up EPCS Before the First Controlled Prescription A standard e-prescribing connection does not automatically establish EPCS readiness. Each prescriber needs the appropriate credentials, authorization, and access to a compliant application. ### Use a Prescriber Readiness Checklist Before go-live, verify: - The clinician has appropriate state prescribing authority and DEA registration for the intended prescribing activity. - Required identity proofing is complete. - The EPCS application has the required third-party audit or certification documentation under DEA rules. - Logical access controls have been established using the required authorization process. - The prescriber has functioning two-factor authentication and understands its use. - Staff permissions distinguish prescription preparation from controlled-prescription signing. - The practice has procedures for lost authentication devices, staff departures, and suspected credential compromise. DEA rules include a two-person process for granting relevant EPCS access, with specific role requirements. Ask the vendor to explain how its implementation meets those requirements rather than substituting an informal administrator approval. Never share a signing credential or authentication device. Staff may prepare permitted prescription information, but the authorized prescriber must review and sign using their own credentials. ## Build a Repeatable Prescription Review Electronic workflows remove handwriting problems, not clinical or selection errors. Incorrect strengths, conflicting directions, and wrong-pharmacy selections remain possible. ### Check the Clinical Context First Confirm the patient, allergies, current medications, relevant conditions, and intended treatment. For controlled medications, assess substance-specific risks and review the prescription drug monitoring program, or PDMP, when required and as clinically appropriate. A PDMP review is distinct from EPCS authentication. Completing one does not satisfy the other. Document the review and any required findings according to applicable rules and practice policy. ### Review the Complete Prescription Before signing, check: - Drug, strength, and dosage form. - Route, frequency, duration, and any as-needed indication. - Quantity and units. - Refill eligibility and number of refills. - Pharmacy name and location. - Consistency between structured fields and free-text instructions. For dermatology, formulation matters: a cream, ointment, solution, and foam are not automatically interchangeable. Specify application sites and instructions clearly, and make sure the quantity fits the intended treatment area and duration. For controlled prescriptions, check schedule-specific restrictions. Schedule II prescriptions cannot be refilled; subsequent prescribing requires a new prescription and applicable safeguards. ## Apply the Workflow to Dermatology Scenarios ### Hypothetical Example: Postprocedure Pain A patient undergoing a dermatologic procedure may need a postoperative pain plan. The clinician first determines whether noncontrolled options are appropriate rather than treating an opioid as a default. If a controlled medication is clinically justified, the workflow should support documenting the rationale, reviewing relevant risks and PDMP information, checking state limits, and providing clear instructions. The prescriber then reviews the prescription and completes EPCS signing. The team should also establish who will handle a pharmacy question after the clinic closes. An unsigned draft does not become a valid prescription merely because the patient is already at the pharmacy. ### Hypothetical Example: Procedural Anxiety A clinician considers a controlled anxiolytic for a future office procedure. The team confirms the intended timing, reviews interacting medications and safety concerns, and communicates any clinician-directed transportation or supervision requirements. Staff should not convert a one-time procedural prescription into an ongoing medication during reconciliation. Clear indication and duration help prevent inappropriate renewal requests. These examples illustrate workflow design, not medication recommendations or dosing guidance. ## Treat Pharmacy Follow-Up as Part of Prescribing Transmission, pharmacy receipt, dispensing, and patient pickup are different events. A successful transmission does not prove that the medication was dispensed. ### Create an Exception Queue Assign ownership for: - Failed or uncertain transmissions. - Pharmacy clarification requests. - Stock shortages and pharmacy changes. - Cancellation requests. - Renewal requests that need a new clinical assessment. For an uncertain transmission, investigate before resending. Automatically creating another prescription can produce duplicates. If a patient requests a different pharmacy, determine whether transfer is permitted and operationally supported. Federal rules allow certain electronic controlled-prescription transfers under specified conditions, but state law and pharmacy capabilities also matter. Do not promise a transfer without confirmation. If replacement prescribing is necessary, coordinate cancellation or other appropriate disposition of the original prescription with the pharmacy. Sending an electronic cancellation request is not the same as confirming that it was processed. ## Connect Prescribing With the Broader Visit Prescribing works better when documentation, communication, and follow-up stay connected. IKON EMR, positioned as “The Ultimate Medical Software,” brings AI-powered EMR/EHR workflows into that broader conversation. An **AI scribe** can help draft visit documentation, but clinicians must verify medication names, indications, and treatment plans. **Telemedicine** can support appropriate follow-up, while controlled-substance prescribing during remote encounters still requires checking current federal and state rules. EPCS alone does not make a telemedicine prescription legally permissible. A **patient portal** provides a channel for instructions and questions; it does not replace required clinical review. **Billing** workflows should reflect the service actually performed and documented, not merely the generation of a prescription. **HIPAA compliance** also depends on practice operations: role-based access, appropriate agreements, secure communications, staff training, and incident procedures. Software alone cannot guarantee compliance. When evaluating IKON EMR, confirm the specific EPCS capabilities, integrations, audit documentation, and implementation responsibilities rather than assuming they are included with general e-prescribing. ## Run a Small Go-Live Review Before expanding the workflow across the practice, use a vendor-approved test environment where available. Do not send fictitious controlled prescriptions to a live pharmacy. Walk through these scenarios: - A new prescriber completes enrollment and authorization. - An authorized staff member prepares a draft for clinician review. - A prescriber cannot access their authentication device. - A transmission fails or its status is unclear. - A pharmacy reports a shortage. - A departing clinician’s access is promptly removed. After launch, review a small sample of prescribing exceptions regularly. Track causes such as incorrect pharmacy selection, incomplete directions, access problems, and duplicate requests. Use those findings to update training and clarify ownership. ## Frequently Asked Questions ### Does EPCS replace a PDMP check? No. EPCS governs electronic controlled-prescription processes. PDMP review is a separate clinical and regulatory responsibility, with requirements that vary by jurisdiction. ### Can staff sign controlled prescriptions for a clinician? No. Authorized staff may prepare information where permitted, but the prescriber must review and sign through their own authorized EPCS access and authentication. ### What happens during an outage? Follow a written downtime procedure. Whether another prescribing method is allowed depends on federal rules, state mandates, the medication, and applicable exceptions. Document the event and reconcile outstanding prescriptions when service returns. ### Where should practices verify requirements? Start with [DEA EPCS guidance](https://www.deadiversion.usdoj.gov/ecomm/ecomm.html), [21 CFR Part 1311](https://www.ecfr.gov/current/title-21/chapter-II/part-1311), state licensing and pharmacy boards, and applicable CMS guidance. Recheck requirements when regulations or prescribing workflows change. A dependable EPCS process combines clinical judgment, secure signing, and accountable follow-through. That combination matters more than how quickly a prescription leaves the screen.